Issue 5 · July 23, 2026 · 5 min read
A Cholesterol Breakthrough
A first-of-its-kind pill could make this powerful treatment easier for millions
For some people, getting cholesterol low enough has meant regular injections. Now the FDA has approved the first daily pill in a powerful family of cholesterol-lowering drugs that until now was available only by injection. And that's not the only breakthrough in today's brief. Researchers uncovered a surprising connection between skin nerves and collagen, while a global study put a number on how much of our longer lives is still spent in poor health. Here's what's worth knowing.
Aging clocks don't agree: Five popular aging clocks tracked different genes and pathways in the same 3,227 adults, a reason not to treat one score as a final verdict.
The brain has more than one drain: Two studies mapped tiny gateways and veins that help clear waste from around the brain; the gateway route weakened with age in mice, showing dementia researchers where to look next.
Inflammation may start with failed cleanup: In old mice, immune cells became worse at clearing spent immune cells; restoring that job lowered inflammation across several organs, suggesting failed cleanup sits upstream of some age-related inflammation.
One brain age can hide different problems: Brain scans found different aging patterns across nine brain disorders, suggesting future tools may need to show where the brain looks older, not just assign one age; the model is still research, not a diagnosis.
Blood pressure between cuff checks: Hilo's $240 first-year system pairs a wrist tracker with a cleared arm cuff to show trends between readings; the wrist device is built for wellness, not diagnosing high blood pressure.
Your health-device data may shape coverage: A federal pilot with Medicare will test whether real-world glucose-monitor data can guide approval and insurance decisions, a step toward using information from devices people already wear; it has no results yet.
The basics still beat biohacking: An investigation of anti-aging claims found the strongest human evidence still belongs to exercise, nutritious food, sleep and close relationships—not the expensive interventions dominating longevity marketing.
Weight-loss drugs enter longevity marketing: Bryan Johnson is promoting popular weight-loss drugs as longevity tools through his health platform, a sign the category is expanding faster than evidence that the drugs extend healthy life in otherwise healthy people.
Featured
A new way to lower stubborn cholesterol—without the shot
For people whose cholesterol stays high despite standard treatment, the next step can be a drug that helps the liver clear more of the cholesterol tied to artery buildup. Until now, every approved option in that family required an injection. The Food and Drug Administration has approved enlicitide, sold as Lipfendra, its first once-daily pill:
The drop was substantial: Across two randomized trials with 3,207 adults, the cholesterol tied to artery buildup fell 56% and 59% more than with placebo after 24 weeks.
The practical win is the pill: People who still need stronger control can now discuss a daily tablet instead of recurring injections.
The outcome that matters most is still open: The trials measured cholesterol, not whether this pill prevents heart attacks or strokes; diarrhea and dizziness were more common in one trial.
This is not another statin. It brings a treatment family once reserved for shots into an ordinary pill bottle, which could make a serious option easier for some people to use.
If your cholesterol remains high despite treatment—or needles have kept this option off the table—there is now a new conversation to have with your clinician.
More this week
Your skin's nerves may help preserve collagen
Skin aging is usually blamed on sun, hormones and time. A new Cell study adds an overlooked player: the nerves woven through skin. Removing those nerves in mice sped collagen loss and aged the cells that make it; restoring one nerve signal reversed some of the damage. Nerves may help skin maintain itself, not just carry sensation.
Human skin samples showed the same pathway weakening with age, but that part of the study was observational and no treatment exists. The useful shift is conceptual: preserving collagen may depend partly on keeping nerves and skin cells talking to each other. It points to a testable pathway, but not to a supplement or cream anyone can use today.
Living longer is not the same as staying healthy
Since 1990, global life expectancy rose 9.2 years, while healthy life expectancy rose 7.2. A new global analysis puts the average gap at 10.7 years worldwide and 14 in the US.
That does not mean every American spends a solid 14 years gravely ill. These are population estimates that add up time lived with disease or disability. But the direction matters: populations have gained more years of life than years in full health. The longevity goal is delaying disability, preserving mobility and extending independence—not adding birthdays alone.
On the radar
Today and tomorrow could reshape the future of compounded peptides in America. FDA advisers are reviewing seven peptide-related ingredient families for possible use by compounding pharmacies. Their recommendation will not change access immediately, but it could influence what pharmacies are allowed to offer next. If one is in your stack, this is the meeting to watch.
Go deeper at longevity.io